CoChat

Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study

Weissman, P., Goldstein, B. J., Rosenstock, J., Waterhouse, B., Cobitz, A. R., Wooddell, M. J., Strow, L. J. · 2005 · Current Medical Research and Opinion
Cited by 71

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Objective: This study was designed to compare the efficacy, safety and tolerability of rosiglitazone (RSG) added to submaximal doses of metformin (MET) with dose escalation to the maximal effective dose of MET monotherapy in type 2 diabetes mellitus.Research design and methods: In this multi-center, double-blind, randomized, parallel-group study, 766 subjects with a baseline MET dose of 1000 mg/day were randomized to receive either RSG 4 mg/day (4 mg/1000 mg) or MET 500 mg/day (1500 mg/day total dose) for 8 weeks. Only the RSG dose was increased in the combination group – to 8 mg/day (8 mg/1000 mg) – and only the MET dose was increased in the MET monotherapy group – to 2000 mg/day for the remaining 16 weeks.Results: After 24 weeks, RSG added to MET (8 mg/1000 mg/day) was at least as effective as 2000 mg/day of MET in improving HbA1c’, with mean reductions of –0.93% (95% CI: –1.06%, –0.80%) and –0.71% (95% CI: –0.83%, –0.60%), respectively, from baseline in subjects that completed the study according to the investigator (mean treatment effect/difference of –0.20% [95% CI: –0.36%,–0.04%]). In addition, a higher percentage of subjects in the RSG + MET group achieved American Diabetes Association target levels of HbA1c < 7% (58.1% versus 48.4%) and American Association of Clinical Endocrinologists target levels of HbA1c ≤ 6.5% (40.9% versus 28.2%). This combination provided significantly greater reductions from baseline in fasting plasma glucose (FPG; –2.29 mmol/L [± 2.37 mmol/L] and –1.12 mmol/L [± 2.41 mmol/L], respectively), with a treatment difference of –0.85 mmol/L (95% Cl: –1.23 mmol/L, –0.47 mmol/L). For the intent-to-treat (ITT) population, the percentage of subjects experiencing a gastrointestinal side-effect was 27.9% and 38.7% for the RSG + MET and MET groups, respectively (OR = 1.63, 95% CI: 1.19, 2.24). Mean body weight (± SD) increased in all randomized subjects treated with the combination therapy (+ 1.79 ± 4.15 kg) compared with a mean weight loss in the up-titrated MET group (–1.78 ± 3.50 kg).Conclusions: This study suggests that addition of RSG to submaximal doses of MET may be a suitable alternative to the maximal effective dose of MET monotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1185/030079905x74844

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 71

Metadata

Authors
Weissman, P., Goldstein, B. J., Rosenstock, J., Waterhouse, B., Cobitz, A. R., Wooddell, M. J., & Strow, L. J.
Venue
Current Medical Research and Opinion
Published
2005-11-04
Volume
21
Issue
12
Pages
2029-2035
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W1972329806
Cited by
71
References
5
FWCI
4.38
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. https://app.cochat.ai/papers/10.1185/030079905x74844
The paper
Weissman, P., Goldstein, B. J., Rosenstock, J., Waterhouse, B., Cobitz, A. R., Wooddell, M. J., & Strow, L. J. (2005). Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Current Medical Research and Opinion. https://doi.org/10.1185/030079905x74844

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.